Please try another search
Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
Name | Age | Since | Title |
---|---|---|---|
Stefan Yee | - | - | Chairman of the Board |
Stijn Van Rompay | - | - | Co-Founder, CEO & Director |
Thomas Jacobsen | - | - | Co-Founder, Chief Business Development Officer & Executive Director |
Leon Van Rompay | - | - | Non-Executive Director |
James Charles Gale | 73 | - | Independent Director |
Marc Foidart | - | - | Independent Director |
Chris Buyse | 59 | 2021 | Independent Director |
Carolyn Myers | 65 | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review